Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07333261
PHASE1
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Sponsor: Susan Bal
View on ClinicalTrials.gov
Summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Official title: A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2026-02-09
Completion Date
2041-12
Last Updated
2026-02-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
BMS-986453
Will be given as a single dose administered by IV infusion.
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States